CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $804,872 | +1576.8% | 53,982 | +391.2% | 0.03% | +900.0% |
| Q2 2021 | $48,000 | -2.0% | 10,989 | +2.8% | 0.00% | +50.0% |
| Q1 2021 | $49,000 | -76.6% | 10,693 | -82.2% | 0.00% | -81.8% |
| Q2 2020 | $209,000 | +703.8% | 59,912 | +239.0% | 0.01% | +450.0% |
| Q1 2020 | $26,000 | -84.9% | 17,673 | -79.8% | 0.00% | -75.0% |
| Q4 2019 | $172,000 | -14.9% | 87,560 | +121.7% | 0.01% | -20.0% |
| Q3 2019 | $202,000 | -86.7% | 39,493 | -81.4% | 0.01% | -88.1% |
| Q2 2019 | $1,519,000 | +24.8% | 212,140 | +131.5% | 0.08% | +13.5% |
| Q1 2019 | $1,217,000 | +157.8% | 91,653 | +52.9% | 0.07% | +94.7% |
| Q4 2018 | $472,000 | – | 59,939 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |